CLINICAL TRIALS PROFILE FOR DONEPEZIL HYDROCHLORIDE

All Clinical Trials for DONEPEZIL HYDROCHLORIDE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000173 ↗	Memory Impairment Study (Mild Cognitive Impairment Study)	Completed	Alzheimer's Disease Cooperative Study (ADCS)	Phase 3	1999-03-01	The National Institute on Aging (NIA) is launching a nationwide treatment study targeting individuals with mild cognitive impairment (MCI), a condition characterized by a memory deficit, but not dementia. An NIA-funded study recently confirmed that MCI is different from both dementia and normal age-related changes in memory. Accurate and early evaluation and treatment of MCI individuals might prevent further cognitive decline, including development of Alzheimer's disease (AD). The Memory Impairment Study is the first such AD prevention clinical trial carried out by NIH, and will be conducted at 65-80 medical research institutions located in the United States and Canada. This study will test the usefulness of two drugs to slow or stop the conversion from MCI to AD. The trial will evaluate placebo, vitamin E, and donepezil, an investigational agent approved by the Food and Drug Administration for another use. Vitamin E (alpha-tocopherol) is thought to have antioxidant properties, and was shown in a 1997 study to delay important dementia milestones, such as patients' institutionalization or progression to severe dementia, by about seven months.
NCT00000173 ↗	Memory Impairment Study (Mild Cognitive Impairment Study)	Completed	National Institute on Aging (NIA)	Phase 3	1999-03-01	The National Institute on Aging (NIA) is launching a nationwide treatment study targeting individuals with mild cognitive impairment (MCI), a condition characterized by a memory deficit, but not dementia. An NIA-funded study recently confirmed that MCI is different from both dementia and normal age-related changes in memory. Accurate and early evaluation and treatment of MCI individuals might prevent further cognitive decline, including development of Alzheimer's disease (AD). The Memory Impairment Study is the first such AD prevention clinical trial carried out by NIH, and will be conducted at 65-80 medical research institutions located in the United States and Canada. This study will test the usefulness of two drugs to slow or stop the conversion from MCI to AD. The trial will evaluate placebo, vitamin E, and donepezil, an investigational agent approved by the Food and Drug Administration for another use. Vitamin E (alpha-tocopherol) is thought to have antioxidant properties, and was shown in a 1997 study to delay important dementia milestones, such as patients' institutionalization or progression to severe dementia, by about seven months.
NCT00004807 ↗	Study of the Pathogenesis of Rett Syndrome	Completed	Johns Hopkins University	N/A	1995-01-01	OBJECTIVES: I. Extend current knowledge of the phenotype and natural history of Rett syndrome (RS). II. Continue the search for a cytogenetic and/or DNA marker. III. Study the effects of cholinergic drugs based on preliminary evidence for reduced levels of brain acetylcholine, while continuing supportive care to modify seizures, respiratory abnormalities, and motor disturbances, and improve nutrition, behavior, and learning. IV. Identify targets for future therapeutic interventions, e.g., growth factors, to influence neurologic recovery.
NCT00004807 ↗	Study of the Pathogenesis of Rett Syndrome	Completed	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	N/A	1995-01-01	OBJECTIVES: I. Extend current knowledge of the phenotype and natural history of Rett syndrome (RS). II. Continue the search for a cytogenetic and/or DNA marker. III. Study the effects of cholinergic drugs based on preliminary evidence for reduced levels of brain acetylcholine, while continuing supportive care to modify seizures, respiratory abnormalities, and motor disturbances, and improve nutrition, behavior, and learning. IV. Identify targets for future therapeutic interventions, e.g., growth factors, to influence neurologic recovery.
NCT00006349 ↗	Donepezil and Vitamin E to Prevent Side Effects Caused By Radiation Therapy to the Head in Patients Receiving Treatment for Small Cell Lung Cancer	Completed	National Cancer Institute (NCI)	Phase 3	2001-02-01	RATIONALE: Donepezil and vitamin E may be able to decrease side effects caused by radiation therapy given to prevent brain metastases in patients with small cell lung cancer. It is not yet known if donepezil and vitamin E are effective in preventing side effects caused by radiation therapy to the head. PURPOSE: Randomized phase III trial to determine the effectiveness of donepezil and vitamin E in preventing side effects caused by radiation therapy given to prevent brain metastases in patients who have small cell lung cancer.
NCT00006349 ↗	Donepezil and Vitamin E to Prevent Side Effects Caused By Radiation Therapy to the Head in Patients Receiving Treatment for Small Cell Lung Cancer	Completed	Alliance for Clinical Trials in Oncology	Phase 3	2001-02-01	RATIONALE: Donepezil and vitamin E may be able to decrease side effects caused by radiation therapy given to prevent brain metastases in patients with small cell lung cancer. It is not yet known if donepezil and vitamin E are effective in preventing side effects caused by radiation therapy to the head. PURPOSE: Randomized phase III trial to determine the effectiveness of donepezil and vitamin E in preventing side effects caused by radiation therapy given to prevent brain metastases in patients who have small cell lung cancer.
NCT00006399 ↗	Effects of Estrogen on Memory in Post-Menopausal Women and Patients With Alzheimer's Disease	Completed	Alzheimer's Association	Phase 2	1999-09-01	The goal of this study is to examine whether the administration of estrogen to post-menopausal women and women with mild to moderate Alzheimer's disease will enhance their memory and their capacity for learning.

Clinical Trial Conditions for DONEPEZIL HYDROCHLORIDE

Condition Name

Condition Name for DONEPEZIL HYDROCHLORIDE
Intervention	Trials
Alzheimer's Disease	88
Alzheimer Disease	50
Healthy	21
Dementia	18

Condition MeSH

Condition MeSH for DONEPEZIL HYDROCHLORIDE
Intervention	Trials
Alzheimer Disease	169
Dementia	51
Cognitive Dysfunction	39
Cognition Disorders	27

Clinical Trial Locations for DONEPEZIL HYDROCHLORIDE

Trials by Country

Trials by Country for DONEPEZIL HYDROCHLORIDE
Location	Trials
United States	787
Japan	171
Canada	96
Germany	68
Korea, Republic of	57

Trials by US State

Trials by US State for DONEPEZIL HYDROCHLORIDE
Location	Trials
California	54
Florida	52
New York	44
Texas	40
Arizona	36

Clinical Trial Progress for DONEPEZIL HYDROCHLORIDE

Clinical Trial Phase

Clinical Trial Phase for DONEPEZIL HYDROCHLORIDE
Clinical Trial Phase	Trials
PHASE4	1
PHASE3	1
PHASE2	5

Clinical Trial Status

Clinical Trial Status for DONEPEZIL HYDROCHLORIDE
Clinical Trial Phase	Trials
Completed	216
Terminated	37
Recruiting	26

Clinical Trial Sponsors for DONEPEZIL HYDROCHLORIDE

Sponsor Name

Sponsor Name for DONEPEZIL HYDROCHLORIDE
Sponsor	Trials
Pfizer	31
Eisai Inc.	24
Eisai Co., Ltd.	11

Sponsor Type

Sponsor Type for DONEPEZIL HYDROCHLORIDE
Sponsor	Trials
Other	250
Industry	231
NIH	39

Donepezil Hydrochloride: Clinical Trials Update, Market Analysis, and Projection

Last updated: April 28, 2026

What is the current clinical-trials landscape for donepezil?

Donepezil hydrochloride is an established symptomatic treatment for Alzheimer’s disease and related dementias. Publicly available trial activity is dominated by late-life comparative studies, formulation work, safety follow-ups, and regional studies rather than large, registration-defining Phase 3 programs typical for new molecular entities.

Key patterns in the clinical-trials landscape include:

• Symptomatic efficacy focus: Trials generally measure cognition and function via standard instruments (for example, ADAS-Cog, CIBIC-plus, MMSE, and related endpoints used historically for cholinesterase inhibitors).
• Regulatory posture: Donepezil’s core indications are well established; current activity tends to be positioned as:
  • comparison against other symptomatic agents,
  • evaluation of dosing regimens and tolerability,
  • formulation, bioequivalence, or real-world effectiveness evidence,
  • subgroup analyses and long-term tolerability.

Which trial types are most active in donepezil research?

Across public registries and publications, current donepezil work clusters into four repeat categories:

1. Comparative and add-on studies
   Donepezil is often used as background standard-of-care in arms that evaluate:

   • memantine combinations,
   • supportive care and behavioral interventions,
   • or other symptomatic agents, depending on local standards.

2. Dosing regimen and tolerability optimization
   Trials examine:

   • titration schedules and adverse-event profiles,
   • persistence/adherence and tolerability in routine care,
   • special populations (elderly, comorbidities).

3. Formulation and pharmacokinetic programs
   Donepezil development remains active through:

   • generic development and bioequivalence studies,
   • formulation optimization (oral dispersible forms, alternative release profiles in some regions),
   • switch studies (for example, from one dosage form to another).

4. Real-world evidence (RWE) and observational registries
   Many studies are designed to quantify:

   • treatment patterns,
   • cognitive trajectory over time,
   • discontinuation drivers and healthcare utilization.

What does the evidence base imply about clinical trajectory?

Donepezil has an established efficacy signal as a symptomatic agent, and trial work is now more about:

• durability of benefit under real-world adherence patterns,
• side-effect management (GI intolerance, bradycardia, weight loss, sleep effects),
• comparative positioning against other symptomatic and disease-modifying approaches.

This matters for market strategy because it tends to shift value away from “novel efficacy” and toward access, tolerability, and product convenience.

How is the Alzheimer’s and dementia market structured for donepezil?

Donepezil sits in the symptomatic Alzheimer’s disease segment that includes other cholinesterase inhibitors (donepezil, rivastigmine, galantamine) and NMDA antagonists (memantine). The competitive environment is shaped by three drivers:

• Standard-of-care penetration: Cholinesterase inhibitors are widely used early to moderate Alzheimer’s symptoms.
• Generic saturation: In many markets, donepezil is heavily genericized, constraining pricing power.
• Shift in prescribing with disease-modifying therapies: Even where disease-modifying agents expand (and clinical protocols evolve), cholinesterase inhibitors often remain part of symptomatic management.

What is the market outlook for donepezil pricing and volume?

Donepezil market performance typically follows:

• Volume growth driven by aging demographics and rising dementia prevalence.
• Revenue pressure driven by generic competition and constrained willingness to pay for symptomatic therapies.

This produces a common outcome:

• units rise, net pricing declines, and revenue growth depends more on market expansion and payer coverage mechanics than on premium innovation.

What demand tailwinds matter most?

The strongest demand-side tailwinds are demographic and care-setting driven:

• Aging populations increase prevalence of Alzheimer’s disease and other dementias.
• Chronic care continuity supports long duration treatment use for symptomatic therapy.
• Primary-care and neurology pathways keep cholinesterase inhibitors as early-line options in many formularies.

What demand headwinds matter most?

The principal headwinds are:

• Generic erosion in major markets.
• Switching dynamics as guidelines incorporate new disease-modifying agents and combination treatment protocols.
• Tolerability constraints that influence discontinuation rates and persistence (especially GI adverse events and cardiovascular effects).

Market projection: how donepezil is likely to perform through 2030

Given donepezil’s maturity and generic penetration, projection should be framed in terms of global category growth vs. share capture by brands and manufacturers rather than premium product expansion.

Base-case projection framework

A practical projection for donepezil typically uses a split:

• Global Alzheimer’s/dementia symptomatic-treated population growth
• Cholinesterase inhibitor share within symptomatic management
• Donepezil share within cholinesterase inhibitors
• Pricing trend under generics and payer pressure

In this framework, donepezil’s outlook is usually:

• positive volume trajectory (aging-driven),
• limited or modest revenue expansion (pricing pressure),
• share capture driven by access, dosing convenience, and formulary preference rather than new clinical efficacy.

Projection ranges (directional)

For an established generic-dominant molecule like donepezil, typical projection shapes are:

• Units: steady-to-mid single digit CAGR, aligned with dementia prevalence growth.
• Revenue: low single digit CAGR or flatter in mature markets, with higher uncertainty in countries where pricing policies remain favorable to legacy brands.
• Regional spread: growth concentration in markets with expanding diagnosis and treatment access, versus flat growth where diagnosis rates and treatment pathways already saturate.

Competitive positioning: what differentiates products in a generic-dominant market?

Since clinical differentiation is limited for the base molecule, differentiation focuses on:

• Formulation and dosing convenience
  • tablet vs. orally disintegrating vs. alternative presentations,
  • patient adherence support.
• Safety management experience and label positioning
  • tolerability data sets used for physician reassurance.
• Access and payer contracts
  • tender wins, formulary inclusion, and net price realization.

How to interpret “clinical trial activity” for investment-grade signals

For donepezil, trial activity is less a proxy for breakthrough efficacy and more a signal for:

• manufacturing expansion and life-cycle management (new forms, bioequivalence programs),
• local regulatory and reimbursement readiness (country-specific studies),
• brand consolidation and supply chain durability.

For business decisions, the main value from ongoing trials is often evidence for:

• comparable performance in real-world titration and persistence,
• safety consistency across populations,
• and switching or substitution feasibility (which affects substitution risk for originators and branded generics).

Key Takeaways

• Donepezil hydrochloride is an established symptomatic Alzheimer’s therapy, and ongoing clinical work is dominated by comparative, tolerability, formulation, and observational evidence rather than new registration-defining efficacy.
• Market growth is primarily demographic and treatment pathway driven, while revenue growth remains constrained by generic pricing pressure.
• The most actionable differentiation is access and product lifecycle management (formulation convenience and payer contracts), not new clinical endpoints.
• Projections through 2030 should be modeled with a volume-up / price-down structure, and regional outcomes should be driven by diagnosis and reimbursement expansion.

FAQs

1) Is donepezil still entering large Phase 3 programs globally?

Donepezil’s current clinical activity is overwhelmingly oriented to evidence refinement, tolerability, and formulation-related programs rather than major Phase 3 efficacy expansions consistent with new molecular registrations.

2) What endpoints do donepezil trials commonly use?

Commonly used measures include cognition and global clinical impression scales such as MMSE and CIBIC-plus, paired with historical Alzheimer’s symptom outcome instruments used for cholinesterase inhibitor evaluation.

3) How does generic competition impact donepezil revenue projections?

Generic saturation typically compresses net pricing, so revenue growth depends more on expanding treated populations and payer volume realization than on premium pricing.

4) What side effects most influence persistence?

GI intolerance and tolerability issues, alongside cardiovascular effects such as bradycardia risk, tend to influence discontinuation and dose adjustments.

5) What product levers matter most in a mature, generic-dominant market?

Formulation convenience, dosing and titration experience, and payer formulary access drive competitive outcomes more than novel efficacy.

References (APA)

[1] National Library of Medicine. (n.d.). ClinicalTrials.gov. https://clinicaltrials.gov/
[2] Food and Drug Administration. (n.d.). Drug approvals and labeling information (Donepezil). https://www.fda.gov/
[3] European Medicines Agency. (n.d.). Assessment reports and product information (Donepezil). https://www.ema.europa.eu/